Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Fig. 1

Differences in the ASAS40 response between secukinumab and placebo at week 16. A MRI and CRP status. B HLA-B27 status. C sex at screening. ASAS, Assessment of SpondyloArthritis international Society; CRP, C-reactive protein; HLA, human leukocyte antigen; M, number of evaluable patients; MRI, magnetic resonance imaging

Back to article page